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Abstract
Myocilin (MYOC) is a 504 aa secreted glycoprotein induced by stress factors in the trabecular meshwork tissue of the eye,
where it was discovered. Mutations in MYOC are linked to glaucoma. The glaucoma phenotype of each of the different
MYOC mutation varies, but all of them cause elevated intraocular pressure (IOP). In cells, forty percent of wild-type MYOC is
cleaved by calpain II, a cysteine protease. This proteolytic process is inhibited by MYOC mutants. In this study, we
investigated the molecular mechanisms by which MYOC mutants cause glaucoma. We constructed adenoviral vectors with
variants Q368X, R342K, D380N, K423E, and overexpressed them in human trabecular meshwork cells. We analyzed
expression profiles with Affymetrix U133Plus2 GeneChips using wild-type and null viruses as controls. Analysis of trabecular
meshwork relevant mechanisms showed that the unfolded protein response (UPR) was the most affected. Search for
individual candidate genes revealed that genes that have been historically connected to trabecular meshwork physiology
and pathology were altered by the MYOC mutants. Some of those had known MYOC associations (MMP1, PDIA4, CALR,
SFPR1) while others did not (EDN1, MGP, IGF1, TAC1). Some, were top-changed in only one mutant (LOXL1, CYP1B1, FBN1),
others followed a mutant group pattern. Some of the genes were new (RAB39B, STC1, CXCL12, CSTA). In particular, one
selected gene, the cysteine protease inhibitor cystatin A (CSTA), was commonly induced by all mutants and not by the wild-
type. Subsequent functional analysis of the selected gene showed that CSTA was able to reduce wild-type MYOC cleavage
in primary trabecular meshwork cells while an inactive mutated CSTA was not. These findings provide a new molecular
understanding of the mechanisms of MYOC-causative glaucoma and reveal CSTA, a serum biomarker for cancer, as a
potential biomarker and drug for the treatment of MYOC-induced glaucoma.
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Introduction
The secreted glycoprotein, myocilin (MYOC), was identified in
human trabecular meshwork (HTM) cells after prolonged
exposure to dexamethasone (DEX) (Trabecular Meshwork Inducible
protein, TIGR) [1]. It was independently discovered in the ciliary
body [2] and in the normal retina [3]. The gene was later found to
be expressed in non-ocular tissues, especially in heart and skeletal
muscle [4]. However, MYOC retained special properties in the
trabecular meshwork and its induction by DEX is specific to this
tissue [5]. Soon after its discovery, mutations in the MYOC gene
were found to be linked to 3–4% of primary open-angle glaucoma
(POAG) [6] and to a large percent (10–30%) to juvenile open-
angle glaucoma (JOAG), an early-onset and more severe form of
the disease [7].
The glaucomas are a group of optic neuropathies caused by the
degeneration and death of the retinal ganglion cells. In glaucoma,
there is a progressive visual field loss and if left untreated, it leads
to irreversible blindness. It is estimated that by 2020 there will be
79.6 million cases of glaucoma worldwide, with a high proportion
of women and Asians [8]. POAG is the most common form of the
disease, which in most cases, is triggered by an elevated intraocular
pressure (IOP). In turn, elevated IOP is the result of an increased
resistance of the trabecular meshwork tissue to the aqueous humor
outflow.
To date, more than 70 MYOC mutations have been associated
with glaucoma (http://myocilin.com/) [9]. Each of the mutations
results in a slightly different phenotype, it is more prevalent in a
given race and some have been speculated to be affected by
environmental epigenetic factors (reviewed in [9]). Nevertheless, in
every case, mutations in MYOC are associated with elevated IOP,
ranging from mild to severe (http://myocilin.com/). Because of
the relevance of this association, the MYOC protein has been
extensively studied.
Myocilin is a 504 amino acid protein with a molecular weight of
55–57 kDa [10,11]. The gene maps to 1q23–q24 [6] and contains
three exons, which pretty much define three protein folding
domains [4,10]. The N-domain (aa 1 to 202) contains a signal
peptide cleavage, a leucine zipper-like motif and is similar to the
heavy chain of myosin [4,10]. The C-terminal domain (aa 244 to
505), separated by a central linker (aa 203 to 205), is 40%
homologous to olfactomedin, a major component of the extracel-
lular matrix (ECM) of the olfactory neuroepithelium. The original
finding that MYOC mutants mapped to the olfactomedin domain
has held, and today, over 90% percent of pathogenic mutations
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myocilin.com/).
Although considerable progress has been made, many questions
regarding the function of wild-type MYOC and the molecular
correlations of the different mutant variants to disease severity
remain. Myocilin is processed and shed inside vesicles [12,13]. In
contrast to the wild-type, recombinant mutants in the olfactome-
din domain, whether generic, glaucoma-associated, stop or
missense, are unable to exit the cell in all cell types tried
[5,12,14,15]. Our earlier work also showed that mutant MYOC
proteins lacking the olfactomedin domain are misfolded, form
insoluble aggregates and accumulate in the endoplasmic reticulum
(ER) [11]. Further, presence of increasing amounts of the
recombinant mutant induces a fraction of the soluble, wild-type
MYOC to move to the insoluble fraction and hamper its secretion
[11]. Glaucoma-associated mutants are likewise insoluble [16] and
hetero-oligomers with the wild-type are sequestered in the ER
[17], leading to ER stress, activation of the unfolded protein
response (UPR) and potential cytotoxicity [18,19]. This data,
supported by clinical findings on the absence of POAG in
homozygous patients for certain MYOC mutants [20] led to the
conclusion that MYOC-linked glaucoma was due to a gain of
function.
In addition to glucocorticoids, MYOC expression is induced by a
number of stress factors. Mechanical stretch, TGF-b, oxidative
stress, heat shock and elevated IOP all induce MYOC in cells and
tissues (review in [21,22]. In addition, expression of MYOC
mutants sensitizes cells to oxidative stress [23]. Myocilin interacts
with several intracellular and extracellular matrix proteins (review
in [24]). Recently it was shown to interact with components of the
WNT signaling pathway [25], which was independently found to
be associated to regulation of IOP [22,26].
In the ER, MYOC undergoes an intracellular endoproteolytic
cleavage in the central linker domain [27,28]. This processing
occurs in ,40% of the wild-type protein and yields a 35 kDa
fragment which is co-secreted with the full-length [28]. Myocilin
mutants inhibit the proteolytic processing and the extent of
inhibition has been correlated with the severity of the glaucoma
phenotypes [28]. In addition, this proteolytic process modulates
the molecular interactions of myocilin and reduces the formation
of myocilin homoaggregates [29]. The enzyme responsible for this
cleavage has been identified as Calpain II [30], a calcium-
dependent cysteine protease present in most mammalian tissues.
All these findings put together reveal the potential involvement
of many different genes in the functions leading to the MYOC-
linked glaucoma. Previously, we reported a first microarray
analysis using wild-type MYOC and high density oligonucleotide
Affymetrix U133A GeneChips [31]. To now identify molecular
differences among the effects of the causative glaucoma MYOC
mutants, in this study we conducted an expression analysis on the
transcriptome of primary human trabecular meshwork cells
overexpressing MYOC mutants, and performed the analysis using
the upgraded Affymetrix U133 Plus 2.0 GeneChips. We selected
four representative mutants, based on different clinical outcomes,
populations and/or relevance of the mutated codon. The Q368X
variant is the most common (29% of the diseased causing variants)
and results in a mild phenotype (http://myocilin.com/). Muta-
tions R342K and D380N comprise 0.8% of the causing variants
each, and are very severe, with a mean maximum IOP of 54 and
39 mmHg [32]. Both mutations have been reported only in one
population, that of Ghana in West Africa. However while there is
only one variant utilizing amino acid Arg342, the amino acid
Asp380, highly conserved in all vertebrates, has produced four
disease causing variants (D380N, D380H, D380A, D380G) [9], a
recurrence known to occur very rarely in genetics. These four
variants appear in different populations and in particular, the His
and Ala changes result in intermediate glaucoma phenotypes and
biochemical protein effects [15,28,33]. The last mutation, K423E,
was selected because it occurs in two unrelated Caucasian
populations [20,34], has a severe clinical outcome and exhibits
the interesting feature that homozygous patients do not manifest
the disease [20]. A similar analysis recently published utilized
transgenic flies and analyzed changes in the transcriptome of 2–
3 day old insects’ whole heads [19].
Cystatin A (CSTA) is a member of the cystatin superfamily of
proteins, some of which are active cysteine protease inhibitors,
such as cystatin A (review in [35]). Within the cystatin superfamily,
CSTA is characterized as a stefin [36]. Proteins of the stefin
family, lack carbohydrates and disulfide bonds and have a
molecular weight ,11 kDa. This single chain protein forms tight
complexes and inhibits the activity of papain-type proteases,
cathepsin B, H and L [36], and presumably other intracellular
cysteine protease inhibitors. The short N-terminal region of
CSTA, and in particular the evolutionary conserved Gly-4 residue
has been shown to play a key role in the binding of the CSTA
inhibitor to the target proteases, papain, cathepsin B and L [37].
Mutations of Gly-4 to aminoacids with longer side chains like
arginine were also shown to be more deleterious for the binding
that mutations to alanine or serine which have small side chains
[37]. Cystatin A is present in various tissues (epidermis,
polymorphonuclear granulocytes, liver and spleen) and has also
been found in extracellular fluids [35]. A loss of function mutation
for CSTA was recently linked to two families of Middle Eastern
origin exhibiting exfoliative ichthyosis, a scaly skin disease [38].
Cystatin A is a known myoepithelial cell marker and its
downregulation plays a role in carcinogenesis, from breast to
brain tumors [35]. It is believed that CSTA regulates cellular
proliferation, tumor growth and metastasis. Cystatin A expression
is a negative prognostic marker in breast tumors of lymph node
negative patients [35]. Recently, levels of CSTA in serum,
together with manganese superoxide dismutase and MMP2, were
shown to be reliable biomarkers for the detection of nasopharyn-
geal carcinomas patients [39].
In the present study, we searched for genes and mechanisms
affected by overexpression of four myocilin mutants in primary
human trabecular meshwork cells. Using microarray profiles, we
found that the myocilin mutants altered a high number of genes
which had been previously associated with trabecular meshwork
physiological and glaucomatous conditions. Some genes were
shared by all mutants while some were mutant-specific. The
extracellular matrix gene ontology (GO) category was the most
enriched and most significant. Of the four most common
mechanisms, genes in the UPR list were changed the most. More
important, this study uncovered cystatin A, a cysteine protein
inhibitor induced by all mutants, which reduced the processing of
wild-type myocilin in vitro. These findings provide a molecular
insight into mechanisms that trigger MYOC-glaucoma and raise
the possibility of using silencing or inhibition of CSTA as a
potential treatment of the MYOC-mutant development of
glaucoma.
Materials and Methods
Generation of Adenoviruses Carrying Wild-type and
MYOC Glaucoma-associated Mutants
Plasmids carrying point mutations corresponding to four human
MYOC mutations genetically linked to glaucoma were generated
by site-directed mutagenesis using as a template clone pMC2 [11]
Mutant Myocilin Altered Genes Identification
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[19]. The plasmids contained the MYOC mutations Q368X,
R342K, D380N, and K423E (Figure1). All mutant clones were re-
amplified with 59-KpnI-39-BamHI ended primers to remove the
PmeI site (MYOC nucleotides (nt) 4–1566) (all MYOC nt numbering
is from access number AF001620) and subcloned into pCR2.1
(Invitrogen, Carlsbad, CA) for confirmation of sequence and
presence of the mutations (clones pGL6, pGL9, pAC10, pAC14).
KpnI-NotI restricted mutant cDNA fragments (1,596 nucleotides)
were gel purified and inserted into pShuttle-CMV (generously
donated by B. Vogelstein [40] for the generation of the
recombinant adenoviral plasmid vectors (pGL7, pGL10, pAC11,
pAC15). For the wild-type, the pKM1 plasmid (see below) was
digested with KpnI-NotI and the isolated fragment inserted into the
same pShuttle-CMV vector to yield pAC18 (total insert 1,601 bp
containing 46 bp 59 and 33 bp 39plasmid sequences flanking the
1,522 MYOC wild-type coding region).
The shuttle vectors were then linearized with PmeI and
electroporated into BJ5183-Ad1 cells for homologous recombina-
tion with an adenovirus backbone plasmid using the AdEasy
Adenoviral Vector System (Stratagene) following manufacturer’s
recommendations. The resultant Ad plasmid vectors (pGL8,
pGL11, pAC12, pAC16, pAC19) were linearized with PacI and
calcium phosphate-transfected (Clontech, Mountain View, CA)
into early passages QBI-Human Embryonic Kidney (HEK) 293A
cells (Qbiogene, Montreal, Quebec, Canada) for the production of
the adenoviral recombinants (Adh.Q368X, Adh.R342K,
Adh.D380N, Adh.K423E and Adh.MYOCWT). These viruses
therefore carry each of the four MYOC mutants driven by the same
CMV promoter. High titer stocks were obtained by propagation in
the same QBI-HEK 293A cells and purification by double binding
CsCl density centrifugation as described [41]. A control virus
carrying the same promoter and no transgene (Ad5.CMV-Null)
was purchased from Qbiogene (Montreal, Canada) and grown and
purified in our laboratory. For Adh.Q368X, the virus particle
number was determined by measurement of its optical density at
260 nm using the formula 1 mg of DNA=2.2 X 10
10 particles. For
the remaining recombinants, physical particles were titered as viral
genomes (vg)/ml as described [41] using a MYOC fluorescent
TaqMan primers/probe Hs00165345_m1 (Applied Biosystems,
ABI, Foster City, CA) and the MYOC plasmid pAC12 for the
generation of the standard curve. Viral infectivity (infectious units
[IFU]/ml) was measured with a rapid titer kit (AdenoX; Clontech)
also as described [41]. Viral lots used in these studies had
concentrations between 2 X 10
11 and 1 X 10
12 vg/ml with
infectivity values between 2 X 10
9 and 5 X10
10 IFU/ml A second
set of viral stocks were grown at the University of North Carolina
Vector Core facility. All viral stocks used in the experiments were
checked for the overexpression of MYOC mRNA by TaqMan
PCR (probe Hs00165345_m1) and MYOC protein by western
blot (goat anti-human polyclonal, Santa Cruz Biotechnology
#21243, Santa Cruz, CA)).
Primary Culture of Human Trabecular Meshwork Cells
Primary human trabecular meshwork (HTM) HTM-72 and
HTM-137 cell lines were generated respectively from the
trabecular meshworks dissected from residual cornea rims of 29
and 39 years old donors (North Carolina Eye Bank) after surgical
corneal transplants at the University of North Carolina Eye Clinic.
The tissue was cut into small pieces, carefully attached to the
Figure 1. Schematic representation of MYOC wild-type and mutant proteins used for the adenoviral constructions. Myocilin protein
contains a signal peptide cleavage (aa 1–50) and three folding domains. An N-terminal myosin domain (aa 50–203), a linker region (aa 203–245), and
C-terminal olfactomedin domain (aa 245–504). All four selected mutants have mutations in the C-terminal olfaction domain. The Q368X mutation
produces a truncated protein.
doi:10.1371/journal.pone.0036301.g001
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with a drop of MEM Richter’s Modification medium (IMEM,
HyClone, Thermo Fisher Scientific, Waltham, MA) supplemented
with 20% heat-inactivated fetal bovine serum (FBS, GIBCO
catalog # 16140-071), 50 mg/ml gentamicin (Invitrogen). Cells
from these specimens were not treated with enzymes and were
allowed to grow from the explant for a period of 4 weeks changing
the media every other day; upon confluency, cells were harvested
and stored in liquid nitrogen. When reconstituted, these primary
non-transformed cells are grown in complete medium consisting of
IMEM, heat inactivated 10% FBS, gentamicin and subsist for
seven to eight passages. In this study all cells were used at passage
4. These outflow pathway cultures comprise all cell types involved
in maintaining resistance to flow. That includes cells from the
three distinct regions of the trabecular meshwork plus cells lining
the Schlemm’s canal. Because most of the cells in these cultures
come from the trabecular meshwork, they are commonly referred
to as ‘‘trabecular meshwork cells’’.
Delivery of Recombinant Adenoviruses to Primary
Human Trabecular Meshwork Cells
Human trabecular meshwork primary cells at passage 4, seeded
on either 3 cm or 10 cm dishes, were grown to between 65–90%
confluency, washed twice with PBS and exposed to the recombi-
nant adenoviruses (Adh.Q368X, Adh.R342K, Adh.D380N, Ad-
h.K423E, Adh.MYOCWT and Ad5.CMV-Null) in 1 ml or 3 ml
serum-free medium respectively. Multiplicity of infections (moi)
ranged from 1.6 X10
3–1.6 X10
4 vg/cell and were randomly
distributed among the replicas. After exposure to the virus for
90 min, complete media was added and incubation continued for
48 h or 72 h. Mutant-Null infections were always performed in
the same day, but interspersed replicas expand over two years.
Although FBS lot number was not recorded in each experiment,
the same supplier, same catalog number of heat inactivated FBS
was used in all experiments.
RNA Extraction, Reverse Transcription and TaqMan-PCR
Assays
Human trabecular meshwork cells cells were scraped from tissue
culture dishes with guanidine thiocyanate buffer (RLT, Qiagen,
Valencia, CA). Total RNA was extracted by loading the solution
onto a QIA Shredder
TM column (Qiagen) and continued by the
use of the RNeasy Mini kit with on-column RNase-free DNAse
digestion according to manufacturer’s recommendations (Qiagen).
Purified RNA was eluted in 30 ml RNase-free water and the
concentration measured with a NanoDrop ND-100 spectropho-
tometer (Thermo Fisher Scientific). Total RNA recoveries
averaged 65.463.6 mg and 11.961.1 mg per 10 and 3 cm culture
dishes respectively. RNA quality was assessed by measuring the
size distribution on an Agilent Bioanalyzer (Agilent Technologies,
Santa Clara, CA).
Reverse transcription (RT) reactions were conducted with 1 mg
HTM cells RNA in a 20 ml total volume of proprietary RT buffer
with RNAse inhibitor (High Capacity cDNA kit) (ABI) following
manufacturer’s recommendations (25uC 10 min, 37uC 2 h, 85uC
5 min, then 4uC). Fluorescently labeled TaqMan probe/primers
sets for human MYOC, CSTA, CXCL2, IGF1, MMP1, MMP3,
MMP12, SFRP1, STC1, SNCA, RAB39B, THBD and 18S RNA
were purchased from the ABI TaqMan Gene Expression Assays
(ABI). The human probes used were: MYOC (Hs00165345_m1),
CSTA (Hs00193257_m1), CXCL2 (Hs00235956_m1), IGF1
(Hs00153126_m1), MMP1 (Hs00233958_m1), MMP3
(Hs00968305_m1), MMP12 (Hs00899662_m1), SFRP1
(Hs00610060_m1), STC1 (Hs00174970_m1), SNCA
(Hs01103383_m1), RAB39B (Hs00293395_m1) and THBD
(Hs000264920_s1). All but one probe corresponded to sequences
from different exons. The 18S RNA probe corresponded to
sequences surrounding position nucleotide 609 (Hs99999901_s1).
Reactions were performed in triplicate 20 ml aliquots using
TaqMan Universal PCR Master mix No AmpErase UNG, run
on an Applied Biosystems 7500 Real-Time PCR System, and
analyzed by 7500 System SDS v.2.0.4 software (ABI). Relative
Quantification (RQ) values between treated and untreated samples
were calculated by the formula 2
2DDC
T where CT is the cycle at
threshold, DCT is CT of the assayed gene minus CT of the
endogenous control (18S), and DDCT is the DCT of the normalized
assayed gene in the treated sample minus the DCT of the same
gene in the untreated one (calibrator). Because of the high
abundance of the 18S rRNA used as the endogenous control and
in order to get a linear amplification, RT reactions from treated
and untreated samples were diluted 10
4 times prior to their
hybridization to the 18S TaqMan probe. Statistical analysis was
performed by the Student’s t-test.
RNA Microarrays Hybridization
The RNAs from cells infected with MYOC mutants viral
recombinants were prepared for hybridization to Human Genome
U133 Plus 2.0 (n=17) GeneChips (Affymetrix, Santa Clara, CA)
at the University of North Carolina Functional Genomics Core
Facility. These oligonucleotide microarrays contain 54,678 probe
sets representing approximately 39,500 well-characterized human
genes. The level of transcription of each gene represented on these
chips is measured using the 11 nucleotide sequences which
comprise each probe set. For the hybridization, total RNA
(,0.7 mg) was reverse transcribed into cDNA using a cDNA kit
from Life Technologies with a T7-(dT)24 primer. Biotinylated
cRNA was then generated from the cDNA reaction using the
BioArray High Yield RNA Transcript Kit. The cRNA was then
fragmented in fragmentation buffer (5X fragmentation buffer:
200 mM Tris-acetate, pH 8.1, 500 mM KOAc, 150 mM
MgOAc) at 94uC for 35 min before the chip hybridization.
15 mg of fragmented cRNA was then added to a hybridization
cocktail (0.05 mg/ml fragmented cRNA, 50 pM control oligonu-
cleotide B2, BioB, BioC, BioD, and cre hybridization controls,
0.1 mg/ml herring sperm DNA, 0.5 mg/ml acetylated BSA,
100 mM MES, 1M [Na
+], 20 mM EDTA, 0.01% Tween 20).
10 mg of cRNA was used for hybridization. Arrays were
hybridized for 16 h at 45uC in the GeneChip Hybridization
Oven 640. The arrays were washed and stained with R-
phycoerythrin streptavidin in the GeneChip Fluidics Station
450. After this, arrays were scanned with the GeneChip Scanner
3000 7G Plus. Sample quality was assessed by examination of 39 to
59 intensity ratios of certain genes.
GeneSpring Analyses
Row data CEL files from Affymetrix were imported into
GeneSpring GX Expression Analysis software, version GS10
(Agilent Technologies). For analysis of expression changes between
the MYOC mutants, MYOC wild-type and null infected samples,
their files were pre-processed through the Robust Multichip
Average (RMA) and replicas from each of the mutant, wild-type or
control chips were grouped using the grouping feature of the
program. An interpretation was created which identified the
treated versus the control selecting average over replicates in each
of the two conditions. To eliminate genes expressed at lower levels
in at least one out of the conditions compared, normalized data
Mutant Myocilin Altered Genes Identification
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at a lower cutoff value of 50.
To identify top-changers, data were subsequently filtered on
Fold Change (FC) to select genes that exhibited at least a 1.5-fold
increase or decrease in the MYOC infected cells. Variance of the
samples was obtained by the unpaired t-test. Lists with genes
altered FC $1.5 were generated in GS10 and exported to the hard
drive. These original gene lists contain many annotations with no
Entrez number, repeated annotations with the same Entrez gene,
a few annotations recognizing more than one Entrez number
(almost identical genes, often pseudogenes) as well as genes
encoding hypothetical proteins and undefined open reading
frames genes. Using standard excel sorting applications, we used
a rational approach to clean and filter FC 1.5-fold gene lists for
each of the redundant and the undefined genes parameters (see
results below). Heat maps of the full range FC of the mutants on
categories of genes from a given function (calcification, elastin
collagen crosslinking, WNT signaling pathway, stress and UPR
response and molecular signature of glaucoma) were created in GS
v7.3. The custom made gene-function lists contained one
Affymetrix ID per gene. In the case that one of the genes from
the list was represented by more than one Affymetrix ID in the
chip, we chose the ID which was more altered by the Q368X
mutation. Overlapping Venn diagrams were created in GS10 with
re-imported gene lists containing Entrez numbers (IDs with no
Entrez removed). Gene ontologies of the overlapping gene list
altered in all-mutants were created in GS v7.3. They were
obtained from the GO SLIMS lists available in the GS7 software,
which contain subsets of the terms in the whole GO.
Microarray Data Submission
All microarray data is MIAME compliant and the raw data has
been deposited in the ArrayExpress MIAME compliant database.
The accession numbers of each of the five experiments along with
login information are as follows:
Experiment name: MYOC.Q368XvsNull
ArrayExpress accession: E-MEXP-3427.
Username: Reviewer_E-MEXP-3427
Password: ebr8fswC
Experiment name: MYOC.R342KvsNull
ArrayExpress accession: E-MEXP-3435.
Username: Reviewer_E-MEXP-3435
Password: nzsut632
Experiment name: MYOC.D380NvsNull
ArrayExpress accession: E-MEXP-3434.
Username: Reviewer_E-MEXP-3434
Password: uuvvpXH4
Experiment name: MYOC.K423EvsNull
ArrayExpress accession: E-MEXP-3439
Username: Reviewer_E-MEXP-3439
Password: Ljwhbanh
Experiment name: MYOC.WTvsNull
ArrayExpress accession: E-MEXP-3440
Username: Reviewer_E-MEXP-3440
Password: kdXjkn3s
Plasmids and Transfections
A human MYOC full coding recombinant expression vector was
generated by amplifying pMC2 with primers 59CACCTGCAAT-
GAGGTTCTTCTGTG3’ (forward) and 59TTTTCA-
CATCTTGGAGAGCTTGAT3’ using Platinum Taq DNA
Polymerase (Invitrogen) and cloning of the gel purified insert into
pCDNA3.1D V5-His-TOPO (Invitrogen). The new plasmid,
pKM1, contains 1522 bp (from -4ATG to TGA+3) of wild-type
MYOC cDNA (19–1540 nt). A MYOC-V5 fused clone was
generated by amplifying pKM1 with the same forward primer
and a 59TTTCATCTTGGAGAGCTTGATGTC3’ (reverse)
which skips the stop codon (19–1534 nt) using high fidelity
Advantage HD Polymerase Mix (Clontech). The gel purified
fragment was incubated with pCDNA3.1D V5-His-TOPO to
yield plasmid pMG29. A pCDNA3.1D V5-His-TOPO empty
(CMV promoter, no transgene) was obtained during the sequence
screening of above cloning procedures (pEmpty). All plasmids were
transformed in TOP10 cells (Invitrogen) and confirmed by
sequence. A TrueORFGold clone of human CSTA (stefin A) was
obtained from Origene (Rockville, MD, cat.# RC203115). The
pCSTA plasmid contains the full coding CSTA cDNA (nt 130–424
accession # NM_005213) fused to Myc-DDK tags. A TrueORF-
Gold clone of human mutant CSTA (CSTAm) was designed and
custom ordered to Origene. The CSTAm was obtained by site-
directed mutagenesis of the codon GGA at nucleotide 10–12 of the
ORF, coding for Glycine, to AGG coding for Arginine [37].
Change of the evolutionary conserved Gly-4 residue has been
shown to decrease affinity of the binding of the CSTA inhibitor to
Cathepsin B [37]. Plasmid DNAs were isolated either using either
a Midi-Prep plasmid kit (QIAGEN) or a PowerPrep
TM HP
Plasmid Purification kit (Origene), which results in lower toxicity
after the nucleofector transfection (unpublished).
Transfection of HEK293 cells was performed by the standard
calcium phosphate method precipitating 7 mg of DNA
(pMG29:pCSTA or pEmpty 1:2.5) in 120 mM calcium phosphate
(Clontech) per 3 cm dish, 40% confluent cells. After overnight
exposure, cells were quickly washed with 1 mM EGTA/PBS, and
incubated in IMEM 2% FBS for an additional 48 h. A change of
medium was done 24 h before harvesting. Transfection of primary
HTM cells was performed using nucleofector technology (Amaxa
Lonza, Basel, Switzerland), their basic kit for Primary Mammalian
Endothelial Cells and the protocol previously described [42].
Briefly, cells were split 24 h before transfection, trypsinized,
counted, and centrifuged at 100 g for 10 min. Cell pellets were
resuspended in the proprietary mammalian endothelial solution at
a concentration of 4 X 10
5 cells/100 ml. Plasmid DNA encoding
the V5-fused MYOC protein (pMG29) was mixed with that of
plasmids encoding either the DDK-fused CSTA (pCSTA) or an
empty transgene (pEmpty) and added to the cells at a total of 3 mg
(pMG29:pCSTA or pEmpty 1:2). Cells-DNA solution was
electroporated on the nucleofector apparatus (Amaxa Lonza)
using program T-23 and allowed to recover for 15 min in pre-
warmed serum-containing media inside the CO2 incubator.
Following the recovery period, cells were gently transferred to
warm medium-containing 3 cm dishes. After 24 h, media was
changed with IMEM 10% serum followed by replacement with
serum-free media 8 h later. Cells were then maintained for an
additional 24 h (48 h post transfection) before being harvested for
the extraction of proteins.
Western-Blots and Antibodies
Proteins extracted from transfected HEK293 and HTM
primary cells were assayed for levels of the different forms of the
MYOC protein. Cultured media was collected and saved.
Adhered cells were washed 2X with cold PBS and scraped from
the dish with 100 ml of modified RIPA buffer containing 1X
protease inhibitor cocktail (Roche Applied Science, Indianapolis,
IN). Aliquots of 4 ml from either the cell lysates or the media were
mixed (1:2 vol) with Laemmli buffer (Bio-Rad, Hercules, CA)
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PAGE Tris-HCl polyacrylamide gels (Bio-Rad). After running,
gels were electro-transferred to PVDF membranes (Bio-Rad),
blocked with 5% nonfat dry milk (Bio-Rad) in PBS-0.2% Tween
20 (Sigma-Aldrich, Saint Louis, MO) for 2–5 h and incubated at
4uC for 3 h to overnight with anti-V5 mouse monoclonal antibody
(Invitrogen) (1:400). Primary antibody reaction was followed by
incubation with anti-mouse IgG secondary antibodies conjugated
to horseradish peroxidase (1:2000; Pierce Biotechnology, Rock-
ford, IL) for 1 h at room temperature. Immunoreactive bands
were visualized by chemiluminescence ECL Plus western blotting
detection system (GE Healthcare Biosciences, Piscataway, NJ) and
membranes were exposed to X-ray film (BioMax MR; Kodak,
Rochester, NY). For controls, blots were re-probed with a
monoclonal anti b-actin (synthetic peptide) (Sigma) (1:5000) and
a monoclonal anti-DDK (synthetic peptide) (1:200) (Origene) for
1 h at room temperature and overnight at 4uC, followed by anti-
mouse IgG secondary antibodies conjugated to horseradish
peroxidase (1:5000; Pierce Biotechnology). Full length and
processed MYOC bands were captured using a Chemi System
equipped with a GelCam 310 camera, PCI digitizing image
acquisition board, EpiChemi II Darkroom with transilluminator
and VisonWorksLS image acquisition software v.7.0.1 (UVP,
Upland, CA). Densitometry of each band was performed with the
provided software to obtain mean intensity values (average of
intensities of all pixels of band region, minus average intensity of
the background pixels). Default background is equal to the sum
total of the perimeter around each band region, three pixels wide.
The percentage of the processed band in each treatment was
calculated by dividing its mean density by the sum of the mean
density of the process plus unprocessed bands.
Results
Adenoviral Vectors Carrying four MYOC Mutants Linked
to Glaucoma
The adenoviral vectors were constructed as indicated in
methods and the MYOC mutant proteins encoded by their inserted
cassettes are shown in Figure 1. Prior to the generation of RNA to
hybridize to the Affymetrix chips, the mutants vectors were tested
on HTM cells for the overexpression of MYOC RNA and proteins
using TaqMan PCR and WB as described above. Upon
normalization to 18S, the levels of MYOC RNA on cells infected
with each of the mutants over the levels of MYOC RNA on cells
infected with Ad.Null increased significantly for all mutants.
Infection with Adh.Q368X produced the truncated form of the
protein while Adh.R342K, Adh.D380N and Adh.K423E pro-
duced the same size protein as the wild-type. Although the
TaqMan mRNA levels produced by Adh.K423E mutant were
similar to those of the other mutants, the levels of its produced
protein were the lowest, indicating either a higher susceptibility to
degradation of this MYOC mutant protein, or a lower recognition
by the antibody due to faulty folding.
Number of Genes Altered in HTM Cells Overexpressing
each of the Four MYOC Mutants
To gain a first insight into the extent of changes occurring in the
transcriptome of HTM cells overexpressing MYOC mutants we
counted the number of genes altered between the mutants and
controls cells (cells infected with Ad5.CMV-Null viruses). To
further understand the differences caused by the mutants and the
wild-type, we re-analyzed the comparisons using the chips of the
MYOC mutants versus those of the MYOC wild-type. To override
the potential differences between primary cell lines derived from
different individuals, all overexpression experiments were con-
ducted in the same cell line at the same passage (HTM-72, passage
4).
All comparisons were done using non-redundant lists of
overexpressed genes. For this, the gene lists generated in Gene
Spring were cleaned according to the following criteria. Affymetrix
IDs that did not have an Entrez number were removed. In the few
cases where one Affymetrix probe set ID number recognized more
than one gene (usually almost identical genes or pseudogenes), one
of them was selected. In the cases of redundant Entrez numbers,
that is, when there were several Affymetrix IDs for the same
Entrez number, we selected the ID that had been most altered.
Using replicas for each of the mutants and for the controls
(Adh.MYOC n=10, 2 per construct; Ad.CMV-Null n=7) and
selecting the methodology and filters outlined above, we generated
lists of 1.5-fold altered genes. Out of the 54,678 spots in the array,
the total number of non-redundant genes altered $1.5X was
higher in the wild-type than in each of the mutants (Figure 2A).
Overexpression of the wild-type induced the change of 4,337
genes while that of the Q368X mutation, which was the second
highest, altered 2,603 genes. While the number of genes altered in
the D380N (2,237) and K423E (2,283) mutations were pretty
similar to those changed by the stop mutation, the mutation
R342K induced only 803 changes in the HTM transcriptome
(Figure 2A). From the total number of altered genes, the number
of up- and downregulated seemed to be similar in wild-type and
mutants with approximately one-half of the total altered in each
category. The highest difference was observed in the R342K
mutant, which had a higher number of downregulated genes (274
genes up- and 529 genes downregulated) (Figure 2A).
When comparing the number of genes altered in the mutants
with those altered in the wild-type, we found that the stop
mutation Q386X had the highest difference with a total of 6,716
(3,342 up and 3,374 down) (Figure 2B). Overall, looking at this
parameter, it appeared that the mutants fell into two groups with
considerably different patterns. The mutations Q368X and
R342K had similar gene number changes and were much higher
than those of D380N and K423E which in turn were similar to
each other (1,411 and 1,384). Together this result on the absolute
number of altered genes indicates that different MYOC mutants
can alter the HTM transcriptome to a different extent and could
therefore have a different severity outcome on the function of the
tissue.
Selected Top-changers Trabecular Meshwork Relevant
(TMR) Genes from MYOC Mutants Induced Lists
The 100 top-changers (50 upregulated and 50 downregulated)
(p#0.05) from each of the mutants compared to Ad5.CMV-Null
are submitted as supporting material (Tables S1, S2, S3, and S4).
To generate these lists we started with the non-redundant lists
obtained above and rationally eliminated those ID numbers with
annotations for LOC hypothetical proteins, FAM (family w/
sequence similarity), noncoding RNAs and pseudogenes. Myocilin
was the most upregulated gene in all lists except in that of the
K423E mutant, serving as a control of the overexpression. Levels
of overexpressed MYOC were identical after infections with
Q368X and R342K, and about half after D380N, though still at
the top of the list (Tables S1, S2, S3, S4, S5, and S6). TaqMan
PCR confirmed that the K423E mutant was highly overexpressing
MYOC, so its absence from the top gene in the array list was
interpreted as a low efficiency of this mutant’s cDNA to hybridize
to the MYOC Affymetrix gene chip spot.
To further get an insight into the extent of how many of those
MYOC mutant-induced genes were encoding trabecular meshwork
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36301Figure 2. Wild-type MYOC and different MYOC mutants alter different gene numbers on the trabecular meshwork transcriptome.
Adenoviral vectors carrying either wild type, four MYOC mutations cassettes or no transgene (Ad5.CMV-Null) were infected on primary human
trabecular meshwork cell line HTM-72 to overexpress MYOC proteins. The expression of genes in the wild-type or mutant-treated cells was obtained
using Affymetrix GeneChips (n=17). GeneSpring 10 and Excel software were used to generate non-redundant gene lists with cutoff fold-change
values of $ and # 1.5. A: number of genes altered in cells treated with the wild-type or each of the mutants compared with the number altered in
cells treated with the empty virus (Adh.WT/Mutants versus Ad5.CMV-Null). B: number of genes altered in cells treated with the each of the mutants
compared with the number altered in cells treated with the wild type virus (Adh.Mutants versus Adh.WT).
doi:10.1371/journal.pone.0036301.g002
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among the four mutants, we screened each of the FC 1.5 lists for
TMR. For this analysis, we separated the up- and downregulated
genes of each mutant list, sort them by FC and, without taking into
account the microarray p-values, scrolled down to rationally select
20 genes from each direction with TM and/or glaucoma-related
functions (TMR) (total 160 genes). Then, we performed a manual
cross-check and identified whether each of the selected genes in
each mutant was present in the other three (Figure 3A and 3B).
Overall, we had a total of 75 unique TMR genes altered in any
of four MYOC mutants, many of which had previously been
reported as responders to glaucomatous insults in independent
studies. Eight genes were altered in all the mutants. Ras-related
protein 39B (RAB39B), Cystatin A (CSTA) and Extracellular matrix
protein 2 (ECM2) were upregulated, while Endothelin 1 (EDN1),
Angiopoietin 2 (ANGPT2) and Stanniocalcin 1 (STC1) were downreg-
ulated. Chemokine (C-X-C) ligand 12 (CXCL12) and Insulin-like growth
factor 1 (IGF1, Somatomedin C) showed different regulation
depending on the mutants.
The upregulated TMR genes induced by the Q368X mutant
appeared to be more similar to those induced by R342K and
different from those induced by D380N and K423E. Thus,
including the all-common genes, 14 out of the 20 TMRs (70%) in
Q368X were shared by R342K while only 6 and 7 in each of these
were shared by either D380N and/or K432E respectively.
Interestingly, upregulated D380N and K423E lists shared a higher
similarity between themselves (12 out of 20, 60%).
The dowregulated TMR genes induced by the Q368X, were
however very similar in the four mutants. Thirteen out of 20
downregulated TMR in Q368X were altered in R342K and all
genes but one, Lysyl oxidase-like 1 (LOXL1), were altered in D380N
and K423E. LOXL1, a gene recently linked to pseudoexfoliation
glaucoma [43] was altered only by the Q368X mutation.
Among the altered genes shared by Q368X and R342K
(mutant set #1) and not by D380N and K423E (mutant set #2),
were Tachykinin 1 (TAC1), Protein disulfide isomerase A4 (PDIA4),
Cadherin 15 (CDH15), Apoptosis regulator BCL2 (BCL2) and CYP26B1.
The TAC1 gene, encoding the precursor of neuropeptide
substance P, was previously identified as a mechanosensitive gene
in the human trabecular meshwork intact tissue [22,44]. Protein
disulfide isomerase A4, which plays a key role in protein folding,
had been found to be altered by TGFb2, DEX and by elevated
IOP in the trabecular meshwork tissue during the homeostatic
response period [44–46].
Among the genes altered by set #2 and not by set #1 mutants
we found Aldo-ketoreductase 1 (AKR1C1), Angiopoietin-like 2
(ANGPTL2), Fibronectin 1(FN1), Matrix metallopeptidase 3
(MMP3) and a-Synuclein (SNCA), which affect various functions,
such steroid metabolism, inflammatory signaling and ECM
organization. The synucleins are proteins highly expressed in the
brain and are involved in presynaptic signaling and membrane
trafficking.
Two of the all-common genes (IGF1 and CXCL12) support the
notion that mutant’s set #1 had similar effects on the trabecular
meshwork transcriptome, which were different from those of set
#2. Expression of IGF1 and CXCL12 was down in set #1 and up
in set #2. Insulin growth factor 1 was classified as an individual
responder to elevated IOP in human perfused organ cultures and
pressure [22] while CXCL12 is a member of the same chemokine
family as CXCL2, a general responder to elevated IOP. Another
case where MYOC mutants had opposite effects on a given gene
was that of Podoplanin (PDPN), a lymphatic marker regulated by
elevated IOP. Podoplanin is upregulated by D380N and K423E
while is downregulated by Q368X.
There were only a few TMR genes that were altered by just one
mutant. These were: Lysyl oxidase-like 1 (LOXL1) (downregulated by
Q368X), Procollagen C-endopeptidase enhancer 2 (PCOLCE2) (down-
regulated by R342K), Pigment epithelium-derived factor (PEDF) (down-
reguled by D380N), Lysyl oxidase-like 2 (LOXL2) and Cytochrome
P450 1B1 (CYP1B1) (downregulated by K423E), and Bone
morphogenetic protein 2 (BMP2) and Fibrillin 1 (FBN1) (upregulated
by K423E). Curiously, three of these genes have been genetically
linked to glaucoma [43,47,48], suggesting an additional physio-
logical link of the mutants with glaucoma at the molecular level.
Another trabecular meshwork gene previously known to be
altered under other insults (IOP and DEX) was Thrombomodulin
(THBD) [45]. Thrombomodulin is a vascular endothelial cell
receptor that binds to thrombin and is involved in the inhibition of
blood clotting. It has been speculated that THBD plays a role in
maintaining the fluidity of the aqueous humor [45]. In this study,
THBD was downregulated in all but the K423 mutant, suggesting
a potential detrimental effect caused by the MYOC mutants. The
same occurred with insult-altered metallopeptidases Matrix metallo-
peptidase 3 (MMP3)( Stromelysin 1) [49] and Matrix metallopeptidase 12
(MMP12)( Macrophage elastase) [22] which were shown downregu-
lated here by the MYOC mutants suggesting that they would
contribute to a decrease outflow.
Although many of the rationally selected TMR genes had
significant microarray FC values, some of them had not. Thus, a
representative sample of ten genes with no significant microarray
p-values in at least one mutant were analyzed in triplicate by the
more rigorous TaqMan PCR assay in a different primary cell line.
HTM-137 and HTM-134 lines were infected with Adh.Q368X,
Adh.R342K, Adh.D380N, Adh.K423E plus the control Ad.Null
viruses, their RNA extracted at 48 h post-infection and reversed
transcribed. Results are included in Table S5. Although not in
every case the absolute TaqMan FC alteration value was similar to
that of the microarray data (different individual, different culture
and different viral stock), only four of the forty TaqMan assays
performed showed a p-value higher than 0.05. Of the four (MMP1
and SFRP1 in Adh.Q368X and MMP12 and SFRP1 in
Adh.K423E), two of them had a p,0.05 in the microarrays
(Table S5). The remaining of the genes exhibited highly significant
p-values in all mutants (Table S5).
Altogether these results indicate that overexpression of MYOC
mutants share many elicited changes with other known glaucoma-
tous insults. Further, they indicate that distinct MYOC mutants
Figure 3. MYOC mutants’ top-changers contained numerous human trabecular meshwork relevant genes. Adenoviral vectors carrying
four MYOC mutations cassettes and no transgene (Ad5.CMV-Null) were infected on primary human trabecular meshwork cell line HTM-72 to
overexpress MYOC mutant proteins. The expression of genes in the mutant-treated cells was compared with that of the cells treated with the empty
virus, using Affymetrix GeneChips (n=15). Non-redundant gene lists from the cutoff FC value of $ and # 1.5 of each mutant were screened for
trabecular meshwork relevant (TMR) genes. Each selected TMR gene was manually cross-checked to identify its expression in the other three mutants.
A: twenty selected upregulated TMR genes in Q368X, R342K, D380N and K423E. B: twenty selected downregulated genes in Q368X, R342K, D380N
and K423E.
doi:10.1371/journal.pone.0036301.g003
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transcriptome.
Pattern of Expression of Trabecular Meshwork Relevant
Functions (TMR.F) Gene Lists in the Four MYOC Mutants
Next we investigated the overall expression pattern of set of
genes known to be associated with selected TMR.F. In other
words, we wanted to know whether genes involved in calcification
mechanisms [50], collagen-elastin cross-linking functions [51], the
WNT signaling pathway [22,25,26] and stress response had been
affected by overexpression of MYOC mutants. We custom made
comprehensive gene lists of the four mechanisms each containing
20–21 genes, and ran heat maps against the complete FC lists of
each of the MYOC mutants (Figure 4). Each row of the map
represents the response of a single gene to the overexpression of
each of the four MYOC mutants, expressed in FC of the MYOC
mutant- versus Ad5.CMV-Null infected cells. Each column
represents the set of genes selected per category. The range of
the FCs of the genes in the calcification, collagen-elastin and WNT
maps by all mutants was between +2.1- and 23.3-fold. The range
of FC of the stress and UPR genes was much larger, between +8.5
and 22.0-fold. Altered MYOC mutant genes which did not pass
the minimal expression criteria (absent signals) have no color and
appear as gray-cells. Overall, most of the genes of in each of the
four functional categories were up or down regulated by at least
one of the MYOC mutants and only a few were not affected in any
mutant (represented by yellow colors). The trend of the similarities
of the mutants in set #1 distinct from those in set #2 can be also
seen here, mostly on genes with highest or lowest changes.
Calcification genes. The mutation Q368X downregulated
most of the genes in the calcification category, including Matrix Gla
(MGP), an inhibitor of calcification and one of the ten most
abundant genes in the trabecular meshwork [52,53]. Concurrent-
ly, Q368X upregulated BMP2, an inducer of calcification and
bone formation which loses its activity upon binding to the
inhibitor MGP [54]. These two changes together would suggest
that the Q368X mutant is prone to induce calcification in the
HTM cells which in turn would provoke hardening of the tissue
and reduce outflow facility. In contrast, the same MGP gene was
upregulated in the set #2 mutants, where BMP2 was moderately
reduced, indicating a different degree of involvement of this
pathway by different MYOC mutants. The Connective Tissue Growth
Factor (CTGF) gene, which has been extensively studied for its
relevance in ECM deposition in trabecular meshwork function
[55] was the less altered in all mutants, and Collagen type 1 alpha 1
(COL1A1), an important structural component of the trabecular
meshwork ECM, was downregulated in the four mutants assayed.
Genes like Osteomodulin (OMD) and Osteoglycin (OGN, also known as
Mimecan), members of the SLPRs family of proteoglycans were
markedly upregulated only by mutant R342K and appeared
downregulated by Q368X. These two genes are markers of
osteoblast differentiation [56], and respond to mechanical stress
[44,46]; OGN was found upregulated in tissues from POAG
patients [57]. Another gene, Periostin (POSTN, also known as
Osteoblast- specific factor2), secreted by osteoblasts, was highly
upregulated only in K423E. Periostin was previously shown to
be upregulated by the glaucomatous insults of mechanical strain
and TGFb2 [58,59]. Lastly, Transglutaminase2 (TGM2), which
catalyzes the cross-linking of numerous ECM proteins, whose
presence in vascular smooth muscle cells (VSMC) is key to
mineralize their matrix and which is present in the aqueous humor
of glaucomatous patients [60] was very much downregulated in
Q368X (Figure 4 upper left panel).
Collagen-Elastin Crosslinking. The most upregulated
genes in this TMR.F category were Fibrillin 2 (FBN2) and to a
lesser extent Lysyl oxidase (LOX). They were induced with different
intensities in mutant’s set #1 Q368X and R342K. Lysyl oxidase is
an enzyme involved in post-translational modifications of collagen
and elastin and in the formation of intra/intermolecular cross-
links, and FBN2 is involved elastic fiber assembly. Lysyl oxidase-
like 1, which is linked to Pseudoexfoliation (PEX) glaucoma, and
which is heavily bound to the PEX material of PEX patients was
very downregulated in Q368X, while other two PEX relevant
components [51], FBN1 and Fibulin 5 (FBLN5), were slightly altered
in all four mutants. The mutation D380N most dowregulated
Versican (VCAN), another PEX component and mechanical strain
regulated gene [44], and two metalloproteinases/inhibitors,
ADAM metallopeptidase 20 (ADAM20) and Tissue inhibitor of
metalloproteinases 3 (TIMP3), which are involved in maintaining
the balance of the ECM and therefore affecting the elastin
network. Overall it seemed that the effect of the four MYOC
mutants had subtle effects on genes involved in the formation of
the elastin network and that such light effect was mostly that of
downregulation (Figure 4 right panel).
WNT signaling. Genes involved in this pathway were
downregulated preferentially by mutant’s set #1. Mutant
Q368X most downregulated Secreted frizzled-related protein 1
(SFPR-1), an IOP responder gene [22] which is present in
glaucomatous trabecular meshwork cells and causes elevated
pressure [26]. The most differently regulated gene between set #1
and set #2 was Transcription factor 4 (TCF4), which interacts with b-
catenin and mediates transcription of WNT targeted genes. The
upregulation of TCF4 in D380N and K423E could be an
indication that these two MYOC mutants would utilize more the
WNT pathway to induce transcription than the other two. In
contrast, Dickkopf-1 (DKK-1), an antagonist that prevents activation
the WNT pathway, was downregulated by all mutants, especially
by D380N. Two of the genes of this pathway, the intronless
transmembrane receptor Frizzled family receptor 10 (FZD10), and the
WNT protein inhibitor WNT inhibitory factor 1 (WIF1), were not
expressed in these set of trabecular meshwork cells (Figure 4, lower
left panel).
Stress and Unfolded Protein Response (UPR). Because
MYOC mutants are known to accumulate in the ER and thus affect
the UPR [11,18,19,23], we next examined the expression of
twenty genes encoding the most common stress proteins (Figure 4,
lower right panel). We found that expression of genes in the stress
category was considerably affected by the MYOC mutants.
Furthermore, expression of these genes was clearly different in
set #1 and #2 mutants. The mutant having a major effect on this
TMR.F was the stop mutation Q368X. In this mutant, the
expression of all but two of the selected most commonly associated
proteins were markedly altered. Among them the canonical UPR
proteins Bone-inducing protein (BIP), DAN-damage-inducible transcript 3
(CHOP) and Calreticulin (CALR) were markedly upregulated, as well
as chaperones Der1-like protein 3 (DERL3) and heat shock proteins
HSP90B1, DNAJB9 and DJC6. Interestingly, CALR,a nE RC a
+
binding protein that binds to the glucocorticoid receptor, together
with Stress-induced-phosphoprotein 1 (STIP1) was one of the most down
regulated protein in the set #2 mutants. Another protein in which
the direction of expression was clearly reversed in both sets was
SNCA, an important component of the amyloid plaques in
Alzheimer patients. SNCA was the most UPR upregulated
transcript in D380N and K423E and the most downregulated in
Q368X and R342K. Except for the NADH dehydrogenase (ubiquinone)
1 alpha subcomplex, assembly factor 1 (NDUFAF1), the UPR proteins
altered in transgenic flies carrying these mutants [19] are also
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system as a good genetic model of glaucoma.
Pattern of Expression of the Physiological Trabecular
Meshwork Biomarkers Gene List in the Overexpressed
Four MYOC Mutants
We next were interested to determine the ability of the MYOC
mutants to alter a set of genes potentially associated with glaucoma
and or glaucomatous insult. The 50 gene list is based on a
previously published potential molecular signature of glaucoma
genes [45]. It is also based on a more recent list of physiological
biomarkers of glaucoma built on a revision of trabecular
meshwork gene expression studies from us and other investigators
(Table S6). The results of the heat map showing the expression of
the 50 genes in all the mutants are shown in Figure 5. All genes
except Endothelial adhesion molecule 1 (ELAM1) were present in all the
mutants, indicating that ELAM1 did not pass the filter set up for
analysis of expression in the HTM-72 cell line. Because expression
of this gene has been detected in whole trabecular meshwork
tissues [22], its absence here indicates a marked downregulation of
the gene when the cells are set up in culture.
Although some of the genes were expressed in set #1 differently
than in set #2, the overall patterns of the different sets was not as
marked as seen in the other gene lists categories. It is interesting to
observe that 78% of the genes from this independent gene list were
shown to be altered more $1.5X in at least one of the four MYOC
mutants (Tables S1, S2, S3, S4, and Figure 3A and Figure 3B), an
indication of the physiological causative role of MYOC in
glaucoma. Very few genes were altered in the same direction in
all four mutants. Two of the three downregulated genes, EDN1
and MMP12, had been mentioned above. The third one,
Parathyroid hormone-like hormone (PTHLH), is a protein that regulates
vascular calcification [61] and that has previously been shown to
be induced by DEX in the trabecular meshwork [62]. Only the
gene encoding Prostaglandin D2 synthase (PTGDS), an enzyme that
catalyzes the conversion of PGH2 to PGD2, was lightly
upregulated in the four mutants.
Overall, a similar number of genes were up- and downregulated
in mutants Q368X, D380N and K423E while R342K showed a
lower number of downregulated genes. However, alteration of
specific genes varied. The genes most altered by Q368X were
TAC1, CDH15, PDIA4 and HSP90B1 (upregulated 43X, 9.7X,
4.6X and 3.3X respectively), and PTHLH, SFRP1 and Thrombos-
pondin2 (THBS2) (all downregulated 22.5X). The mutant R342K
shared the four most upregulated and two of the most
downregulated (PTHLH, SFRP1) with Q368X. Interestingly, the
gene most downregulated by R342K, MMP1 (24.5X), was shared
with the D380N and K423E mutants but not with Q368X, where
MMP1 was upregulated. Mutants D380N and K423E shared
PDPN among their three top upregulated and the metallopepti-
dases MMP3 and MMP12 among the top downregulated. Another
interesting difference among the effect of the four mutants on the
transcriptome was the total lack of expression of TAC1 (precursor
of the substance P neuropeptide) in D380N and K423E, while it
was the most induced gene in Q368X and R342K. Mutant
Q368X was the only one to exhibit genes with unique responses,
that is, with changes in expression that were opposite to the
changes incurred by the other three (MMP1, MMP3 and
Prostacyclin synthase, PTGIS).
Of the four genes induced by the highest number of
glaucomatous insults, Angiopoietin-like 7 (ANGPTL7), PDIA4, Super-
oxide dismutase 1 (SOD1) and Tropomysin 4 (TPM4) (Table S6), only
PDIA4 (upregulated in Q368X and R342K), and TPM4 (down-
regulated in K423E) were markedly altered in some of the
mutants. PDIA4 is an ER protein with isomerase activity on S-S
bonds, and TPM4 is actin binding protein involved in the
contractile system of the cell.
Altogether, these different and common influences on the
transcriptome triggered by the four mutants reveal a potential
molecular reason as to why each of the MYOC mutants have a
distinct clinical outcome and affect a particular group of the
population.
Genes Altered in All Mutants
In addition to finding genes by which each of the mutants may
exert their damage, we were interested in searching for a common
altered gene whose mechanism of action could potentially be
applied to all MYOC-causing glaucomas. For this we compared the
1.5X altered genes from wild-type (Adh.MYOCWT) and
Adh.Mutants using the Venn map feature of the GS10 program.
Because this feature uses the Affymetrix ID numbers for the
comparisons, for this analysis we used 1.5-fold redundant gene lists
(all spots for a given Entrez number included). Fold change $1.5
lists of each of the wild-type and mutants versus the null virus were
created as indicated in methods, exported to the hard drive, and
cleaned of IDs that did not have an Entrez number.
To first get an insight on the extent of sharing changes between
the wild-type and the mutants, re-imported all Entrez lists were
Venn mapped comparing each of the mutants to the wild-type
(Figure 6A). This comparison showed that the number of altered
genes in each mutant that did not overlap with those altered in the
wild-type varied. The stop mutation Q368X contained the highest
number of non-overlapping genes, both in absolute numbers and
in percentage (2,247; 64%) (Figure 6A). The mutation R342K,
whose absolute number of altered genes is the lowest of the
mutants studied (Figure 2), contained 542 non overlapping genes,
which amounts to a still high percentage of the total (56%)
(Figure 6A). The other two mutants (set #2), D380N and K423E
had a lower number of non-overlapping genes (24% and 22%
respectively), sharing more of the changes with the wild-type.
To study the number of genes which were simultaneously
altered in all mutants, we Venn mapped their FC $1.5 lists
(Figure 6B). We found that a total of 73 genes were altered in all
four mutants (Figure 6B).
Enriched Functions of the Mutant Overlapping Gene List
To investigate functions potentially involved in a common
causative action of the four mutants studied, we searched for the
GO enriched functions in the 73 mutant overlapping gene list. We
analyzed the three GO SLIMS major functional categories of
Biological Processes, Cellular Components and Molecular Func-
tions, and sorted them by percent of genes in each of their
Figure 4. MYOC mutants induced changes on genes of trabecular meshwork relevant functions, especially on the UPR. Heat maps of
set of genes representing four relevant trabecular meshwork functions. The four categories gene lists were costumed generated by literature review.
Each row represents the fold change (Adeno.MYOC mutant over Adeno.Null) for a single gene in each of the four mutants. Each column represents
the fold changes for all genes of the category in one MYOC mutant. The fold change for each gene is visually represented by a color, which is given by
the scale bar in the center of the figure. Heat maps were generated with genes lists containing the full range of fold changes. Gray cells indicate that
the expression of the giving gene was below the signal intensity cutoff value and was considered absent.
doi:10.1371/journal.pone.0036301.g004
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diagram of the top seven subcategories from each main group is
shown in Figure 7 top. In Biological Processes, cell cycle
(GO:7049) contained the highest percent of genes number
(23.1%, P#0.0003,) and DNA replication (GO:6260) was the
most significant (P#0.000009, 13.5% genes). In Cellular Compo-
nents, the extracellular region subcategory (GO:5576) was both
the one with highest percentage of genes and most significant
(25.9%, P#0.0001). In the Molecular Function category, the
subcategory with more genes was that of receptor binding
(GO:5102) (15.8%, P#0.0009) while the one most significant
was the ATPase inhibitor activity (GO:42030) (P#0.00008, 3.5%
genes) (Figure 7 top).
Figure 5. MYOC mutants altered most physiological biomarkers of glaucoma. Heat maps of a gene list containing 50 potential biomarkers
for the human trabecular meshwork (Table S6). The biomarker gene list was generated by a comprehensive review of trabecular meshwork
expression studies as indicated in the result section. Each row represents the fold change (Adeno.MYOC mutant over Adeno.Null) for a single gene in
each of the four mutants. Each column represents the fold changes for all biomarkers in one MYOC mutant. The fold change for each gene is visually
represented by a color, which is given by the scale bar at left. Heat maps were generated with genes lists containing the full range of fold changes.
Gray cells indicate that the expression of the giving gene was below the cutoff of signal intensity value and was considered absent.
doi:10.1371/journal.pone.0036301.g005
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shown in Figure 7 lower panel. As expected, some of these genes
coincide with those selected above through other selection means,
ratifying the relevance of their potential involvement in the
association of MYOC mutants with glaucoma. Among the genes,
we observed the signaling cytokine CXCL12, the vasoconstrictor
EDN1, the extracellular matrix constituent ECM2, the cysteine
protease CSTA, the calcium homeostasis proteins STC1, STC2 and
the growth factors IGF1 and FGF1. It is likely that a different
extent combination of the functions encoded by these genes is
what it would cause the MYOC mutants to trigger the development
of the disease.
Genes Altered in All Mutants and not in the Wild-type.
Identification of Cystatin A
Next we were interested to investigate whether the genes altered
in all mutants were also altered in the wild-type. To determine
how many of the 73 genes in the mutants’ overlapping list were
mutant-specific, we performed a Venn map comparing the shared
mutant list with that of the 5,749 genes altered by the wild-type.
Looking for non-overlapping genes, we found that only 10 out of
the 73 genes were altered specifically in all mutants and were not
shared with the altered genes of the wild-type (Figure 8).
Analysis of the functions of the 10 specific genes revealed the
presence of a cysteine protease inhibitor, CSTA(alias Stefin A),
which showed a no change 1.0-fold in the wild-type and an
increase of 3.4-, 3.2-, 1.5- and 1.9-fold in Q368X, R342K, D380N
Figure 6. MYOC mutants shared different gene percentages with MYOC wild-type, and shared 73 genes among themselves. Venn
diagrams of genes differentially altered 1.5-fold in response to overexpression of MYOC wild-type and MYOC-mutants. Each circle represents one
condition. Intersections indicate numbers of genes that are shared between the different conditions. A) genes shared of each of the mutants with the
wild-type. B) genes shared by all mutants.
doi:10.1371/journal.pone.0036301.g006
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overexpressing the MYOC mutants was validated by TaqMan
PCR in a different HTM primary cell line (HTM-137) and using
new viral stocks. Cells were infected with each of the four mutants,
Ad5.CMV-Null and Adh.MYOCWT as indicated in methods.
RNA was extracted 48 h post-infection and its cDNA assayed for
expression of CSTA, using MYOC as a positive control and 18S as
the endogenous calibrator. Results were expressed in FC values of
each of the genes in the treated (MYOCs) over negative control
(Ad5.CMV.Null), and normalized to their own 18S. In cells
infected with Q368X, R342K, D380N and K423E, CSTA was
induced 4.6-fold (P=0.012), 3.7-fold (P=.001), 6.45-fold
(p=0.015), and 5.7-fold (P=0.002) respectively. In cells infected
with Adh.MYOCWT, rather than a no change as it occurred in
the chip, CSTA was reduced 23.0-fold (P=0.0001), a result most
likely due to the highest sensitivity to the TaqMan assay. The
overexpression of MYOC in each of the dishes (mutants and wild-
type infected) was used as a positive control and ranged from 891
to 7,131 FC over that in Ad5.CMV-Null.
Functional Assay of Cystatin A. Involvement in Wild-type
Myocilin Processing
In order to investigate whether overexpression of the selected
CSTA gene would affect the processing of the wild-type MYOC
protein we generated tagged recombinant plasmids, containing
both genes (Figure 9A). Plasmid pMG29 contains 1513 nt of wild-
type MYOC fused to the V5 tag in a pCDNA3.1D V5-His-TOPO
background. Plasmid pCSTA contains the full coding CSTA
cDNA (Origene) fused to the DDK and MYC elements. Plasmid
pCSTAm derives from pCSTA but contains a mutation at
nucleotide 139 (G to A) that converts N-terminal Gly-4 residue to
an Arginine and inactivates the binding of the inhibitor to the
cathepsin B protease [37]. Plasmid pEmpty does not contain any
transgene cDNA (see methods) and was used as a control. pMG29
was co-transfected with either pCSTA or pEmpty in HEK293 and
primary HTM-137 cells in a ratio of 1:2 (Figures. 9B and 9C).
Extracted intracellular and secreted proteins were run in PAGE
gels, blotted and cross-reacted with an antibody against the V5 tag
fused to MYOC. Blots were then re-probed with beta-actin for
equal loading control and with anti-DDK antibody to confirm the
presence of CSTA. The 35 K processed C-terminal appeared as a
doublet. In both cell lines, the processing of the wild-type was
reduced in the presence of the CSTA protein.
In the HEK293 cells secreted fraction, densitometry of the wild-
type and processed C-terminal fragments showed a mean density
of the processed MYOC bands to be a 48.6% of the total secreted
MYOC in the cells transfected with pEmpty and 36.4% in the cells
transfected with pCSTA (a percent reduction of 25.1%). The
difference was more marked in the intracellular fraction where the
processed MYOC was 49.8% of the total in the control and 12.5%
in the cells transfected with CSTA (a percent reduction of 74.9%).
In the primary HTM cells secreted fraction, densitometry of the
wild-type and processed C-terminal fragments bands showed the
mean density of the processed MYOC to be 33.0% of the total
secreted MYOC in the cells transfected with pEmpty controls and
17.2% in the cells transfected with pCSTA (a percent reduction of
47.9%). The difference was more marked in the intracellular
fraction where the processed MYOC was 36.5% of the total in the
control and 6.6% in the cells transfected with CSTA (percent
reduction of 89.1%). Protein extracts were run in duplicate gels
and transfections were repeated on the HEK293 to confirm the
findings. Confirmation of the processing effect of CSTA in wild-
type MYOC was achieved by the transfection and overexpression
of HTM-137 cells with pCSTAm, a plasmid where the activity of
Figure 7. Gene ontology. The ECM category (GO:5576) contained the highest percent and significance of MYOC-induced genes. Top:
enriched GO categories of the 73 gene list shared by all mutants (from Figure 6) sorted by P values. Bottom: genes selected from the categories shown
on top (color coded).
doi:10.1371/journal.pone.0036301.g007
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residue Gly-4 to Arg [37] (Figure 9D). In the secreted fraction,
densitometry readings of the mutant experiments showed the
processed MYOC in cells transfected with pEmpty and pCSTAm
to be 23.6% and 37.1% respectively of the total secreted, while in
cells transfected with pCSTA was 10.5% (percent reductions of
55.5 and 71.7% respectively). In the intracellular fraction, the
processed MYOC was 17.2% and 20.4% of the total MYOC in
cells transfected with pEmpty and pCSTAm and 9.5% in cells
transfected with pCSTA (percent reductions of 44.8% and 53.4%
respectively).
These results indicate that the increased levels of the protease
inhibitor CSTA, but not those of the inactivated CSTA, are able
to inhibit the processing of MYOC. In both cell types the
inhibition occurred in both fractions and the reduction seems to be
higher in the non-transformed trabecular meshwork specific cells
than in the transformed embryonic kidney HEK293 line.
Therefore the previously reported protein processing reduction
observed in the MYOC mutants [28] might be due to
overexpression of CSTA. The finding could lead to a common
treatment of the inhibition of CSTA to ameliorate the development
of the disease caused by MYOC mutants.
Discussion
Our goal in this study was to gain insight into the molecular
mechanisms linking MYOC mutants to the development of
glaucoma. Even if the MYOC gene is expressed in several non-
ocular tissues, MYOC mutants are associated to only one disease,
glaucoma. Because myocilin is induced by a variety of stress factors
(from oxidative stress to mechanical strain), it is very likely that the
disease caused by the MYOC mutants would be aggravated by
their induced overexpression under stress conditions. To date, a
few studies have addressed the effect of overexpressing some
MYOC mutants in ocular and non-ocular cells [15,18,23,28].
However, except for one study in fruit flies [19], most of them
Figure 8. Cystatin A is induced in all MYOC mutants and not in MYOC wild-type. Top: Venn diagram comparing genes altered 1.5-fold in all
MYOC mutants (left circle) with those altered in the MYOC wild-type (right circle) (from Figure 6). Intersection indicates numbers of altered genes
which are shared between all the mutants and those altered in the wild-type. Number of genes specifically altered by the mutants is outside the
intersection and circled in red. Bottom: list of specific genes highlighting Cystatin A and its altered fold change values in each condition.
doi:10.1371/journal.pone.0036301.g008
Mutant Myocilin Altered Genes Identification
PLoS ONE | www.plosone.org 16 May 2012 | Volume 7 | Issue 5 | e36301focused on the effect of the mutants in a few cellular mechanisms.
Because MYOC mutants cause high tension glaucoma in humans,
and because an elevated IOP phenotype is the result of a
dysfunctional trabecular meshwork, here we studied the effect of
overexpressing them in primary non-transformed, human trabec-
ular meshwork cells. With the intent of uncovering new
mechanisms, our approach entailed the examination of global
changes induced by the mutants in the entire transcriptome of the
cell.
Genes, known and New
When we examined the most altered genes induced by all four
mutants, we observed a high number of genes which had been
previously identified as functionally relevant for the trabecular
meshwork at either physiological or glaucomatous stress condi-
tions. Among those genes are EDN1, MGP, IGF1, CALR, PDIA4,
PCLOCE2, MMP1, MMP3, SFRP1, FN1, PDPN, OGN, OSF2,
THBS2, THBD, LOX, LOX-L1, TAC1, Secretogranin II (SCG2) and
SNCA. Some of these had already been reported to be associated
with MYOC mutants (e.g. MMP1, CALR, and PDI) or wild-type
(SFRP1, FN1) in other studies [18,19,41] [25,63], and validates the
finding. However, the association of most of them with MYOC
mutants was unknown.
As is not uncommon in this type of studies, some of the found
genes appeared to serve a counteracting purpose while others
appeared to be directly related to the detrimental effect. For
example, END1 was on the top downregulated list in all four
mutants. Endothelin protein is processed to secrete a potent
vasoconstrictor peptide with a well-established connection to
glaucoma [64]. Endothelin can lower IOP by contracting the
ciliary muscle, but conversely, an antagonist of its receptor can also
lower IOP in glaucomatous monkeys [64]. The endogenous EDN1
downregulation by myocilin mutants seen here is curious. It could
be interpreted as either a signal for contributing to the high IOP
phenotype of the mutants or to a counteracting effect.
A gene that could enlighten the correlation between the mutants
and elevated IOP is MMP1. In this study all mutants but one
(Q368X) downregulated MMP1, while the wild-type upregulated
Figure 9. Cystatin A inhibits the processing of MYOC wild-type in cultured cells. Recombinant expression plasmids containing tag-fused
full coding wild-type MYOC (pMG29), CSTA, and controls plasmids, inactive mutated CSTA (CSTAm) and pEmpty, were generated as indicated in
Methods. pMG29 was co-transfected with either pCSTA, pCSTAm or pEmpty (1:2) and harvested at 48 h post-transfection. Equivalent volumes of cell
extracts and of their supernatants were loaded onto 4–15% SDS-PAGE gels, transferred to PVDF membranes and analyzed by immunoblotting.
Different MYOC protein forms (full length and processed) were detected with an anti-V5 mouse monoclonal followed by an anti-mouse horseradish
peroxidase antibodies. Blots were re-probed with b-actin and DDK antibodies for loading and identification controls. Percent of the MYOC processed
band was calculated by densitometry. A) schematic representation of the expression cassettes of the recombinant plasmids. B, C and D:
Representative western blots with extracts from transfected cells. B) extracts from HEK293 co-transfected by calcium phosphate. C and D) extracts
from primary HTM-137 cells co-transfected by nucleofector electroporation.
doi:10.1371/journal.pone.0036301.g009
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type 1, an important component of the ECM of the outflow tissue.
Increased levels of MMP1 have been extensively associated with
increasing outflow facility and lowering of IOP [41,65]. Therefore,
the MMP1 downregulation observed here could be seen as a
contribution to the build-up of an ECM excess, increase of
aqueous humor resistance and consequent elevated IOP produced
by the mutants. The unexpected upregulation of MMP1 by
Q368X (confirmed repeatedly by TaqMan PCR) could then be
explained as one of the molecular reasons as to why this mutation
causes a milder outcome of the disease. Curiously, we had
previously reported an interesting feedback loop regulation of
expression between the MMP1/MYOC genes [31,41,66], where
overexpression of wild-type MYOC induced the expression of
MMP1 [31] while overexpression of MMP1 reduced that of wild-
type MYOC [41,66]. It is possible that a homeostatic balance
between these two proteins would be disrupted by the presence of
the mutated protein form.
Another potentially relevant gene found in these studies was
PDIA4. In an earlier report overexpressing Q368X in trabecular
meshwork cells, Kee and co-workers [18] had observed increased
PDI levels in the treated cells. In this study PDIA4 expression was
induced by both the Q368X and R342K mutants, but not by
D380N and K423E. This enzyme which catalyzes the formation
and breakage of disulfide bonds is a key component of the protein
folding mechanism. Myocilin folding and complex formation is
relevant for its function and has been known to be mediated by the
formation of covalent disulfide bonds involving its five cysteine
residues [67]. Although the fifth residue 433Cys is not present in
the Q368X stop mutation, the induction of the PDI is bound to
affect the stability of the proteins and even perhaps affect the
secretion of other proteins [68]. In our early work, PDIA4 was
induced in response to elevated pressure [45,46]. It is known that
mechanical strain causes deformation of proteins, triggering them
to unfold and subsequently refold [69]. Protein disulfide isomerase
induction could thus be a mediator of this effect and represent a
cellular defense response against the altered protein, as it also
occurs in Creutzfeld-Jacob disease [70]. Why PDIA4 it is only
induced by two of the mutants is not yet clear and might be a sign
of the different avenues through which each mutant contributes to
the disease.
Some of the genes altered by these mutants were new. These
include among others RAB39B, STC1, CDH15, CXCL12, CSTA,
ECM2 and Lysosomal-associated membrane protein 3 (LAMP3), a gene
which is expressed in lymphoid organs and dendritic cells. Some of
these genes were commonly altered in all mutants while others
where changed only in one or two of them. Their encoded
functions could play a role on the mutant’s linkage to the disease.
Thus, RAB39B, upregulated in all mutants, is a small GTPase
binding protein described as being specific to neurons and
involved in vesicular trafficking [71]. This mechanism, which
includes the ability to secrete the protein, has been shown to play a
key role in myocilin function [12,13] and was suggested to be
disrupted by MYOC mutants [11]. It would be possible that
upregulation of RAB39B could have a role on the trafficking and
non-secretion of the MYOC mutants.
Another new gene, STC1, was in contrast downregulated in all
mutants. Stanniocalcin regulates calcium and phosphate transport
in the kidney and has been postulated to prevent hypercalcemia
[72]. The downregulation of STC1 could be an indication that the
MYOC mutants are favoring a trend towards calcification of the
trabecular meshwork.
Few of the genes encoding proteins reported to interact with
Myocilin made the 1.5X FC cutoff. Two of them did. Secreted
frizzled protein 1, [25] which was downregulated in mutants
Q368X and R342K, and FN1 [63], that was upregulated in
D380N and K423E. The SNCA gene which was also upregulated
in D380N and K423E is from the same family as the MYOC
binding protein c-synuclein, but in contrast, showed no co-
localization and thus, not binding [73]. a-Synuclein, is a protein
abundant in neurons and involved in Parkinson and other
neurodegenerative disorders and in here could play the role of a
pathological chaperone, as it has been described in other systems
[74]. a-Synuclein peptides are a major component of amyloid
plaques in the brains of patients with Alzheimer’s disease [75],
which has been speculated to have some common mechanistic
features with Glaucoma [76].
Differences between Mutants
Overall, there were many similarities between Q368X and
R342K (which we termed set #1). Those similarities were distinct
from the changes induced by the other two mutants D380N and
K423E (set #2). This was an unexpected finding, since there are
not described phenotypic similarities shared between the mutants
of the same group, or described phenotypic differences between
the two groups. At the moment we can postulate that, in addition
to IOP, there may yet be undefined glaucoma biomarkers in the
altered genes pool which could differently influence the develop-
ment of the disease in sets #1 and #2.
A look at the genes representing trabecular meshwork relevant
functions and physiological markers of glaucoma by the use of heat
maps (Figures 4 and 5) revealed that most of genes in those lists are
affected by overexpression of MYOC mutants. The trend of
similarities between the two sets of mutants is clearly seen in the
genes involved in calcification, WNT signaling and stress, while it
is less obvious in those genes encoding collagen-elastin cross-
linking and in the biomarkers’ list. The intensity of the changes
was considerably greater in the stress and UPR function group,
especially for the Q368X mutation. This mutation clearly
downregulated genes that could induce elevated IOP, such
TGM2 and SFRP1 [26,60] while inducing others that have a role
in protein folding, such as CALR and Calnexin (CANX). This
combined regulation could be beneficial and contribute to the
milder outcome of the disease in the Q368X mutant. In contrast,
the lower induction of the same genes (CALR and CANX)b y
R342K, together with the upregulation of the calcification genes
OGN and OMD (heat map Figure 4) could provide this mutant
(otherwise similar to the stop mutation) with the difference needed
to induce an elevated pressure.
Although each of the MYOC mutants exhibited individual
characteristics which are most likely instrumental in triggering
different disease severities, there was a need to search for a
common thread. In a Venn map comparison with wild-type we
observed that the four MYOC mutants exhibited a different
percentage of non-shared altered genes. Set #1 mutants had a
larger non-shared percentage than set #2. This could be an
indication that set #1 would be further away from the proposed
protective mechanism of the wild-type than set #2 or, that these
mutants require a higher number of changes to cause the disease.
When comparing the four mutants against themselves, we found
only 73 altered common genes. And from the 73, only 10 were not
altered in the wild-type.
Cystatin A as a Potential Common Link
One of the genes found elevated in all mutants and not elevated
in the wild-type was CSTA, which encodes for the cysteine protease
inhibitor cystatin A. This gene is present in most tissues, its
expression is associated with tumor growth and it is a serum
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CSTA mRNA by the MYOC mutants is intriguing. Because the
protein involved in the processing of myocilin, calpain II, is a
cysteine protease, and because myocilin cleavage is inhibited by
MYOC mutants, one could reasonably infer that CSTA plays a
role in the inhibition of the process. Whether the elevation of
cystatin A seen here can result also in the inhibition of calpain is
not yet known. Cystatin A is known to inhibit papain and
cathepsins, not calpains. However, a recent study investigating
induced cell death in monocytes and macrophages has shown that
calpain activation occurred downstream of cathepsin B (a CSTA
substrate) [77]. They concluded that cathepsin B activated calpain
[77]. Such finding would implicate that increased levels of cystatin
A would, by inactivating cathepsin B, result in the inactivation of
calpain. In our functional assay, overexpression of cystatin A
reduced the processing of wild-type myocilin while overexpression
of an inactive CSTA did not. This effect could then have been
achieved by either a downstream inactivation of calpain through
the inactivation of cathepsin B, or by a direct cleavage of myocilin
by cathepsin B.
It is important to point out that MYOC-causative glaucoma
occurs only in heterozygous individuals, and that MYOC forms
wild-type/mutant hetero-oligomers which lead to the formation of
insoluble aggregates (gain of function) [12,17]. It would be logical
to assume that myocilin processing, affected by the expression of
the mutants, plays a fundamental role in the formation of the
hetero-aggregates. The fact that hetero-aggregation could also
modulate the extracellular environment [15] provides an addi-
tional support for the relevance of faulty hetero-aggregates in the
development of glaucoma.
Finally, although several mechanisms are bound to be involved
in the association of MYOC mutants to glaucoma, it looks that
activation of cysteine protease inhibitors could be a common,
general one. It would be interesting to investigate whether the
application of an inhibitor to CSTA, such as its siRNA, could
restore the normal MYOC processing and affect the outcome of the
disease. Our results showing that overexpression of an inactive
CSTA reverted the decrease processing would support this
possibility. It would also be of interest to determine whether a
screening of CSTA levels in the serum could be applied to
glaucoma as it is presently occurring in cancer [39].
Conclusions
Our study on the transcripts altered by overexpression of MYOC
mutants in glaucoma-relevant primary human cells provides key
insights on the potential mechanisms leading to the development
of MYOC-linked glaucoma. We uncovered that each mutant’s
phenotype could result from its unique effect on the transcriptome.
We learned that a number of important genes which have been
historically associated with physiological and pathological mech-
anisms of the human trabecular meshwork are altered by the
expression of these MYOC mutants. On overall mechanisms, we
identified that, genes of the UPR pathway were the most affected.
On individual gene analyses, we confirmed the involvement of
previously MYOC-associated genes (e.g. MMP1, PDIA4, CALR,
SFPR1) and revealed the relevance of some new ones (e.g. STC1,
RAB39B, CXCL12). Most importantly, we discovered a mutant-
specific induced gene, CSTA. This inhibitor of cysteine proteases
was functional, and inhibited MYOC protein processing in
cultured cells. We believe these findings do significantly impact
our understanding of MYOC-caused glaucoma and could provide
the basis for the potential development of a broad-spectrum
therapy for the mutant disease.
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